Interim Results
Tristel PLC
13 February 2006
TRISTEL plc
INTERIM RESULTS
Tristel plc ('Tristel'), the healthcare business specialising in infection
control, today announces its maiden interim results for the 26 weeks ended 31
December 2005.
Highlights
•Total sales of £1.79m (eight months to 28 February 2005 (34 weeks):
£1.95m), an underlying increase of 20%
•Profit before tax during the first six months of the financial year was
£327,481 (eight months to 28 February 2005 (34 weeks): £5,455)
•Interim dividend of 0.275p net per share (maiden interim dividend)
•First appointments of overseas distributors concluded in Spain, Portugal,
Belgium, Holland, Luxembourg, Turkey, Pakistan and New Zealand
•Alliance with Johnson Diversey to develop a product range for the
pharmaceutical clean room market
Commenting on current trading Paul Swinney, Chief Executive of Tristel, said:
'The infection control marketplace is vibrant and our core business of supplying
instrument sterilants (in solution and wipe form) to United Kingdom hospitals
continues to grow.We are increasing our share of the domestic market.Having
established a solid platform in our home market in recent years, one of the main
reasons for the IPO was to develop the Company into an international business
and that initiative is now underway.Our first export sales have been made to
overseas distributors that we have selected and appointed since the beginning of
this current financial year.
We are also pleased to announce the pan-European alliance with Johnson
Diversey.It is the first time that our infection control technology has broken
into a major marketplace outside of hospitals.To achieve this with such an
important market force as Johnson Diversey is great testimony to our chemistry.'
For further information, please contact:
Tristel plc Binns & Co PR Ltd
Paul Swinney, Chief Executive Paul McManus (paul.mcmanus@binnspr.co.uk)
Paul Barnes, Finance Director Ben Knowles (ben.knowles@binnspr.co.uk)
Tel:01638 721 500 Tel 020 7786 9600
http://www.tristel.com Mob: 07980 541 893
Chairman's Statement
I am pleased to announce our first interim results as a public company.
We have made good progress during the first half of the 2005/2006 financial
year.Total sales in the first six months were £1.79m compared with £1.95m in the
eight months to 28 February 2005, the accounting period used for the purposes of
the AIM admission which was completed on 1 June 2005.The underlying increase in
first half sales is 20% compared with last financial year.
Our core products are the sterilising solutions and wipes that we supply to NHS
and private sector hospitals for use in endoscopy, day case surgeries, theatres,
ear nose and throat (ENT) and ultrasound departments.We are continuing to
increase our customer base and market share.Additionally, we have expanded the
number of makes of endoscope washing machines that our chemistry can be used in.
The Tristel Duo product, which applies our chlorine dioxide chemistry onto hard
surfaces, has made an encouraging start, having been trialled successfully in
the intensive care and organ transplant units of a major inner London teaching
hospital.We are exploring co-branded distribution opportunities for Duo with
major suppliers of surface cleaning products to the Health Service.
Employing a similar co-branded distribution model, we are entering a new market
for Tristel - pharmaceutical clean rooms - in partnership with Johnson
Diversey.The Tristel chemistry will initially be incorporated in a sporicidal
surface disinfectant for distribution throughout the European Community.The
intention is to develop further chlorine dioxide products for this marketplace.
During the first half we have appointed our first overseas distributors and made
our first export sales.The interest shown in the Tristel chemistry at the major
medical trade shows that we have attended has been extremely encouraging.As we
had anticipated when deciding to join AIM, the background reasons for Tristel's
success in our home market clearly exist overseas.We will continue to pursue
international expansion vigorously.
Operating profits (before exceptional items and net interest income/expense)
were £0.307m in the first half compared with £0.332m in the first eight months
of the previous year, whilst pre-tax profits amounted to £327,481 compared with
£5,455.
Dividend
We are declaring an interim dividend of 0.275 pence per share, in line with our
progressive dividend policy.The dividend will be paid on 6 April 2006 to
shareholders on the register at the close of business on 10 March 2006.
Current trading
We have entered the second half with good sales momentum in our existing
domestic product portfolio and the appointment of our first overseas
distributors augurs well for the future.
Furthermore, we are expanding the number of makes of instrument washing machines
that our chemistry can be used in and we have won a number of substantial
contract awards so far this year
The pipeline of new business opportunities is strong.With our exciting
technology there are many market sectors to target outside of our core hospital
marketplace and there remain applications for our chemistry within hospitals for
which we have still to build a significant level of sales.
To date we have served the United Kingdom hospital market through our own sales
organisation.A complementary strategy for building the Tristel business is to
co-label our chemistry with a partner who has a strong market position in its
sector and is looking for new innovative technology.By pursuing this strategy we
believe we can access distribution whilst continuing to build the Tristel brand.
The partnership with Johnson Diversey is an important development in this
direction.We expect to see more co-branding distribution partnerships emerge in
the months and years ahead.
In summary, the first half result is very pleasing.We will continue to grow and
develop the business and to do so we must exploit the existing product portfolio
to its maximum potential, which means taking it into new sectoral and
geographical markets.We must also continue to innovate with our core technology
and possibly develop or acquire new technologies.The timing of when new products
will make a significant impact on the business is always uncertain, but we do
have a healthy pipeline of new ideas and initiatives.
Francisco A. Soler
Chairman
13th February 2006
GROUP PROFIT & LOSS ACCOUNT
For the 6 months ended 31 December 2005
6 months 8 months Year
ended ended ended
31/12/05 28/02/05 30/06/05
(unaudited) (audited) (audited)
Note £ £ £
Turnover 1,787,447 1,946,794 3,009,115
Cost of sales 814,080 891,412 1,448,048
Gross profit 973,367 1,055,382 1,561,067
Administrative costs 666,749 723,372 1,121,215
Other operating income - - -
Operating profit 306,618 332,010 439,852
Loss on sale of subsidiary - ( 22,275) ( 22,275)
Employee share option costs - ( 278,000) ( 279,956)
306,618 31,735 137,621
Interest receivable and similar 20,863 1,475 5,775
income
Interest payable and similar - ( 27,755) ( 39,200)
charges
Profit on ordinary activities 327,481 5,455 104,196
before taxation
Taxation 2 ( 81,870) ( 36,115) ( 65,440)
Profit/(loss) on ordinary 3 245,611 ( 30,660) 38,756
activities after taxation
Dividends ( 65,551) - ( 119,184)
Retained profit/(deficit) for 180,060 ( 30,660) ( 80,428)
the period
Earnings/(loss) per share 4
Basic 1.03p (0.20)p (0.24)p
Diluted 1.03p (0.20)p (0.22)p
The group has no recognised gains or losses other than as shown above.
GROUP BALANCE SHEET
As at 31 December 2005
As at As at As at
31/12/05 28/02/05 30/06/05
(unaudited) (audited) (audited)
Note £ £ £
Fixed assets
Intangible fixed assets 852,971 498,430 828,832
Tangible fixed assets 123,769 92,618 83,168
976,740 591,048 912,000
Current assets
Stocks 329,248 184,606 224,710
Debtors 604,623 538,676 546,489
Cash at bank and in hand 860,168 88,493 1,212,112
1,794,039 811,775 1,983,311
Creditors:
Amounts falling due within one 929,423 946,099 1,234,015
year
Net current assets/(liabilities) 864,616 ( 134,324) 749,296
Total assets less current 1,841,356 456,724 1,661,296
liabilities
Provisions for liabilities and ( 96,456) ( 303,232) ( 96,456)
charges
Net assets 1,744,900 153,492 1,564,840
Capital and reserves
Called up share capital 238,368 30,667 238,368
Share premium account 1,455,980 183,964 1,455,980
Merger reserve 478,526 478,526 478,526
Profit and loss account 3 ( 427,974) ( 539,665) ( 608,034)
Equity shareholders' funds 3 1,744,900 153,492 1,564,840
GROUP CASH FLOW STATEMENT
For the 6 months ended 31 December 2005
6 months 8 months Year
ended ended ended
31/12/05 28/02/05 30/06/05
(unaudited) (audited) (audited)
Note £ £ £
Net cash (outflow)/inflow from 1 ( 62,210) 166,891 312,543
operating activities
Returns on investment and 2 20,863 ( 25,980) ( 39,018)
servicing of finance
Capital expenditure 2 ( 126,595) ( 182,308) ( 244,006)
Equity dividends paid ( 119,184) - -
Acquisitions and disposals 2 - ( 2,216) ( 1,816)
( 287,126) ( 43,613) 27,703
Financing 2 ( 5,980) 60,059 1,170,268
(Decrease)/increase in cash in ( 293,106) 16,446 1,197,971
the period
Reconciliation of net cash flow 3
to net funds/(debt)
(Decrease)/increase in cash ( 293,106) 16,446 1,197,971
Cash outflow from decrease in - 37,301 423,714
debt and lease financing
Change in net debt resulting ( 293,106) 53,747 1,621,685
from cash flows
Other movements - - -
Movement in net debt ( 293,106) 53,747 1,621,685
Net funds at 1 July 1,153,274 ( 373,425) ( 468,411)
Net funds at 31 December 860,168 ( 319,678) 1,153,274
NOTES TO THE GROUP CASH FLOW STATEMENT
For the 6 months ended 31 December 2005
6 months 8 months Year
ended ended ended
31/12/05 28/02/05 30/06/05
(unaudited) (audited) (audited)
Note £ £ £
1. Reconciliation of operating profit to net cash (outflow)/inflow from operating
activities
Operating profit 306,618 332,010 439,852
Depreciation charges 75,737 42,631 64,902
Loss on disposal of fixed assets 273 1,082 1,082
Increase in stocks ( 118,693) ( 174,006) ( 214,110)
Increase in debtors ( 58,134) ( 174,904) ( 190,723)
(Decrease)/increase in creditors ( 268,011) 140,078 211,540
Net cash (outflow)/inflow from ( 62,210) 166,891 312,543
operating activities
2. Analysis of cash flows for headings netted in the cash flow statement
Returns on investment and
servicing of finance
Interest received 20,863 1,475 5,775
Interest paid - ( 27,139) ( 44,478)
Interest element of hire purchase - ( 316) ( 315)
payments
Net cash inflow/(outflow) for 20,863 ( 25,980) ( 39,018)
returns on investments and
servicing of finance
Capital expenditure
Purchase of intangible fixed ( 80,236) ( 52,985) ( 197,838)
assets
Purchase of tangible fixed assets ( 49,359) ( 137,350) ( 54,195)
Sale of tangible fixed assets 3,000 8,027 8,027
Net cash outflow for capital ( 126,595) ( 182,308) ( 244,006)
expenditure
Acquisitions and disposals
Disposal of subsidiary - ( 2,216) ( 1,816)
Net cash outflow for acquisitions and - ( 2,216) ( 1,816)
disposals
Financing
New loans in year - 20,000 20,000
Loan repayments in year - ( 53,587) ( 440,000)
Hire purchase capital repayments - ( 3,714) ( 3,714)
in year
Directors' loans repaid ( 5,980) - ( 7,952)
Share issues - 17,001 1,596,575
Share buyback - - ( 75,000)
Government grant received - 80,359 80,359
Net cash (outflow)/inflow from ( 5,980) 60,059 1,170,268
financing
3. Analysis of changes in net At 1.7.05 Cash flow At 31.12.05
debt
£ £ £
Net cash:
Cash at bank and in hand 1,212,112 ( 351,944) 860,168
Bank overdrafts ( 58,838) 58,838 -
1,153,274 ( 293,106) 860,168
Debt:
Hire purchase - - -
Debts falling due within one year - - -
Debts falling due after one year - - -
- - -
Total 1,153,274 ( 293,106) 860,168
NOTES TO THE INTERIM REPORT
For the 6 months ended 31 December 2005
1. Basis of preparation
The accounts of the Group for the 6 months ended 31 December 2005, which are
unaudited, were approved by the Board on 6 February 2006. They have been
prepared in accordance with the accounting policies set out in the Annual Report
and Accounts for the year ended 30 June 2005.
The results contained in this statement do not constitute statutory accounts as
defined in Section 240 of the Companies Act 1985. The financial information for
the full preceding year is based on the statutory accounts for the year ended 30
June 2005. Those accounts, upon which the auditors, Hedges Chandler, issued an
unqualified audit opinion, have been delivered to the Registrar of Companies.
The financial information for the 8 months ended 28 February 2005 is based on
the accounts for that period prepared by Deloitte & Touche LLP for the purpose
of the AIM Admission Document in May 2005.
2. Taxation
Taxation for the 6 months ended 31 December 2005 is provided at 25% on profit on
ordinary activities, being the anticipated rate of taxation for the period.
3. Reconciliation of movements in shareholders' funds
6 months 8 months Year
ended ended ended
31/12/05 28/02/05 30/06/05
(unaudited) (audited) (audited)
£ £ £
Profit/(loss) for the financial 245,611 ( 30,660) 38,756
period
Dividends ( 65,551) - ( 119,184)
180,060 ( 30,660) ( 80,428)
New share capital subscribed - 187,003 1,666,719
Share related charges (UITF 17) - 228,000 207,600
Purchase of own shares - ( 75,000) ( 75,000)
Net additions to shareholders' 180,060 309,343 1,718,891
funds
Opening shareholders' funds 1,564,840 ( 154,051) ( 154,051)
Closing shareholders' funds 1,744,900 155,292 1,564,840
Equity interests 1,744,900 155,292 1,564,840
4. Earnings per share
6 months 8 months Year
ended ended ended
31/12/05 28/02/05 30/06/05
(unaudited) (audited) (audited)
£ £ £
Profit/(loss) for the financial period 245,611 ( 30,660) 38,756
after taxation
Weighted average number of ordinary 23,836,820 15,297,247 16,050,830
shares for basic earnings per share
Weighted average number of ordinary 23,836,820 15,297,247 18,002,893
shares for diluted earnings per share
The weighted average number of shares for the periods shown above takes account
of a four for one bonus issue of shares on 23 May 2005.
5. Copies of Interim Report
Further copies of the Interim Report may be obtained from the Company's
Registered Office at, Tristel plc, Lynx Business Park, Fordham Road, Snailwell,
Cambs, CB8 7NY, UK.
This information is provided by RNS
The company news service from the London Stock Exchange